Tags

Type your tag names separated by a space and hit enter

Specific properties and effect of perindopril in controlling the renin-angiotensin system.
Am J Hypertens 2005; 18(9 Pt 2):142S-154SAJ

Abstract

Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. Its efficacy, safety, and tolerability are well established in the treatment of hypertension and heart failure. Moreover, large morbidity-mortality trials, such as the EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) and Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS), have shown that antihypertensive treatment with perindopril reduces and prevents cardiovascular disease in a large range of patients with vascular diseases, whether or not they are hypertensive. Thus, the outcomes of these and other trials support the concept of cardiovascular protective properties of angiotensin-converting enzyme inhibition with perindopril in addition to the obvious blood-pressure-lowering effect. Considering its properties and the clinical evidence on efficacy and tolerability that has been gathered, perindopril fulfils the criteria of the latest guidelines for hypertension and cardiovascular disease management and should therefore be considered as a first-line antihypertensive agent, forming a consistent part of the comprehensive strategy against hypertension and related cardiovascular complications.

Authors+Show Affiliations

Division of Cardiology, University Hospital of Ferrara, Corso Giovecca 203, 44100 Ferrara, Italy. fri@dne.unife.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16125051

Citation

Ferrari, R, et al. "Specific Properties and Effect of Perindopril in Controlling the Renin-angiotensin System." American Journal of Hypertension, vol. 18, no. 9 Pt 2, 2005, 142S-154S.
Ferrari R, Pasanisi G, Notarstefano P, et al. Specific properties and effect of perindopril in controlling the renin-angiotensin system. Am J Hypertens. 2005;18(9 Pt 2):142S-154S.
Ferrari, R., Pasanisi, G., Notarstefano, P., Campo, G., Gardini, E., & Ceconi, C. (2005). Specific properties and effect of perindopril in controlling the renin-angiotensin system. American Journal of Hypertension, 18(9 Pt 2), 142S-154S.
Ferrari R, et al. Specific Properties and Effect of Perindopril in Controlling the Renin-angiotensin System. Am J Hypertens. 2005;18(9 Pt 2):142S-154S. PubMed PMID: 16125051.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Specific properties and effect of perindopril in controlling the renin-angiotensin system. AU - Ferrari,R, AU - Pasanisi,G, AU - Notarstefano,P, AU - Campo,G, AU - Gardini,E, AU - Ceconi,C, PY - 2005/05/10/received PY - 2005/05/27/accepted PY - 2005/8/30/pubmed PY - 2006/1/6/medline PY - 2005/8/30/entrez SP - 142S EP - 154S JF - American journal of hypertension JO - Am. J. Hypertens. VL - 18 IS - 9 Pt 2 N2 - Perindopril is a long-acting, once-daily lipophilic angiotensin-converting enzyme inhibitor with high tissue angiotensin-converting enzyme affinity, lowering angiotensin II and potentiating bradykinin. Its efficacy, safety, and tolerability are well established in the treatment of hypertension and heart failure. Moreover, large morbidity-mortality trials, such as the EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) and Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS), have shown that antihypertensive treatment with perindopril reduces and prevents cardiovascular disease in a large range of patients with vascular diseases, whether or not they are hypertensive. Thus, the outcomes of these and other trials support the concept of cardiovascular protective properties of angiotensin-converting enzyme inhibition with perindopril in addition to the obvious blood-pressure-lowering effect. Considering its properties and the clinical evidence on efficacy and tolerability that has been gathered, perindopril fulfils the criteria of the latest guidelines for hypertension and cardiovascular disease management and should therefore be considered as a first-line antihypertensive agent, forming a consistent part of the comprehensive strategy against hypertension and related cardiovascular complications. SN - 0895-7061 UR - https://www.unboundmedicine.com/medline/citation/16125051/Specific_properties_and_effect_of_perindopril_in_controlling_the_renin_angiotensin_system_ L2 - https://academic.oup.com/ajh/article-lookup/doi/10.1016/j.amjhyper.2005.05.037 DB - PRIME DP - Unbound Medicine ER -